Search Results - technology+classifications+%3e+therapeutic+modalities+%3e+small+molecules

153 Results

Sort By:

Sustained release formulations for fat reduction

JHU Ref #: C18159Value Proposition· Sustained release of small molecule that depletes white fat· Local injectable administration with less intense dosing regimenUnmet Need· Excessive white fat accumulation, commonly associated with obesity, is a significant health concern that impacts metabolic, cardiovascular, and endocrine systems....

Published: 3/14/2025 | Inventor(s): Laura Ensign-Hodges, Yub Raj Neupane, Fatemeh Rajaii

Keywords(s):

Category(s): Clinical and Disease Specializations > Endocrinology > Thyroid Disorders, Clinical and Disease Specializations > Metabolic Diseases > Obesity, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Small Molecules

Intranasal Delivery of Testosterone Prodrugs to the CNS

Unmet NeedProstate cancer (PC) is the most common non-cutaneous malignancy in men with over 1.4 million new cases diagnosed globally in 2020 (see Wang 2022). Although disease confined to the prostate is highly curable, many men will be diagnosed with metastatic prostate cancer which is not curable but is treatable. The gold standard of care is androgen...

Published: 3/14/2025 | Inventor(s): Rana Rais, Barbara Slusher, Mark Markowski, Arindom Pal

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology > Prostate Cancer, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Small Molecules

Combination therapy targets intrinsic cancer resistance to nucleoside DNA methyltransferase inhibitors.

Unmet NeedGenome stability is regulated by a variety of mechanisms. One such mechanism is DNA methylation. DNA methylation can alter the manner in which genes are expressed, and aberrations in methylation management are well documented as features of cancer cells. DNA methylation is regulated in part by enzymes known as DNA methyltransferases (DNMTs)....

Published: 3/14/2025 | Inventor(s): Srinivasan Yegnasubramanian, Jianyong Liu, William Nelson, Jun Liu

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology, Technology Classifications, Technology Classifications > Therapeutic Modalities > Small Molecules

Novel Oxazolidinones for Treatment of Bacterial Infections

Marketing Summary DraftNovel Oxazolidinones for Treatment of Bacterial InfectionsJHU Ref #: C14633Value Proposition· Belong to the same chemical family as Zyvox, marketed by Pfizer, but shows better efficacy· Positive activity demonstrated against M. tuberculosis· MIC values the same or better than the current antibiotics in the...

Published: 3/13/2025 | Inventor(s): Gyanu Lamichhane, J. Ippoliti

Keywords(s): Bacterial Infections, Disease Indication, Infectious Diseases, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Infectious Diseases > Bacterial Infections

Small Molecule Neutral Sphingomyelinase 2 (nSMase2) Inhibitors

Unmet NeedNeutral sphingomyelinase 2 (nSMase2) is expressed in neurons and hydrolyzes sphingomyelin, producing the lipid ceramide, which functions in stress responses leading to apoptosis, cell growth arrest, and differentiation. Increased levels of ceramides have been associated with many neurological disorders, including Alzheimer’s disease, multiple...

Published: 3/14/2025 | Inventor(s): Takashi Tsukamoto, Niyada Hin, Ondrej Stepanek, Barbara Slusher, Camilo Rojas, Ajit Thomas

Keywords(s): Antagonists/Inhibitors, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules

Inhibition of nSMase for the Treatment of Human Immunodeficiency Virus Infection

Unmet NeedHuman immunodeficiency virus (HIV) is a retrovirus that negatively impacts the immune system, leading to immunosuppression and increased susceptibility to secondary, opportunistic infections and some cancers. It is estimated that 36.7 million people worldwide are currently living with HIV. Presently, HIV has no cure and requires life-long...

Published: 3/13/2025 | Inventor(s): Norman Haughey, Barbara Slusher, Camilo Rojas

Keywords(s): Antagonists/Inhibitors, Disease Indication, HIV, Infectious Diseases, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Infectious Diseases > HIV

Discovery of Small Molecule Inhibitors of Neutral Sphingomyelinase 2 (nSMase2) for the Treatment of Neurodegenerative Diseases

Unmet NeedIn the brain, neutral sphingomyelinase 2 (nSMase2) is expressed in neurons and increased activity and expression of this enzyme has been associated with pro-inflammatory conditions observed in Alzheimer’s disease, multiple sclerosis and human immunodeficiency virus (HIV-1) patients. Inhibition of human nSMase2 may preserve neuronal function...

Published: 3/13/2025 | Inventor(s): Barbara Slusher, Camilo Rojas, Ajit Thomas, Radim Nencka, Michal Sala, Hubert Hrebabecky, Norman Haughey

Keywords(s): Alzheimer's Disease, Antagonists/Inhibitors, Assay, Clinical Diagnostics, CNS and Neurological Disorders, Disease Indication, In Vitro Diagnostics, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Neurology > Alzheimer's Disease

Prodrug for Immunological and Oncological Therapy

Unmet NeedApproximately 1.24 million hematological cancer cases occur each year, accounting for approximately 6% of all cancer cases (Bristol Myers Squibb). Currently, standard treatment strategies include chemotherapy, radiation therapy, and stem cell transplants. However, there exist several major drawbacks for each method. Stem cell transplants can...

Published: 3/14/2025 | Inventor(s): Barbara Slusher, Rana Rais, Franco D'alessio, Pavel Majer, Marcela Krecmerova, Srinivasan Yegnasubramanian

Keywords(s): Blood Cancer, Cancers, Disease Indication, Inflammatory Disorders, Respiratory Infections, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutic Substance Synthesis Method, Therapeutics, Transplants

Category(s): Clinical and Disease Specializations > Oncology > Hematologic Malignancies, Clinical and Disease Specializations > Transplantation, Technology Classifications > Therapeutic Modalities > Small Molecules

Diagnostic and therapeutic target for primary dysautonomia

Value Proposition:· Diagnostic target for broad primary dysautonomia screening.· Broadly applicable therapeutic target for symptom relief in primary and secondary dysautonomia patients.Technology DescriptionResearchers at Johns Hopkins have identified a potential diagnostic and therapeutic target for patients with primary dysautonomia....

Published: 3/14/2025 | Inventor(s): Malcolm Brock, Frank Bosmans

Keywords(s):

Category(s): Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities > Small Molecules

Alkylsulfenyl Thiocarbonates as Precursors to Hydropersulfides

Unmet Need:According to a survey by the CDC, nearly 50% of Americans age 20 and up have some form of cardiovascular disease (see AHA). The management of cardiovascular diseases depends on the specific indication, and standard therapies include one or multiple of the following types of medications: blood thinners, ACE inhibitors, beta-blockers, calcium...

Published: 3/14/2025 | Inventor(s): John Toscano, Vinayak Khodade, Sahil Aggarwal, Nazareno Paolocci, Blaze Pharoah, Gizem Keceli, Kelsey Zhang

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Cardiovascular, Clinical and Disease Specializations > Oncology

1 2 3 4 5 6 7 8 9 10 ...